These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1011 related articles for article (PubMed ID: 30336540)
1. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test. Dollinger MM; Behl S; Fleig WE Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540 [TBL] [Abstract][Full Text] [Related]
2. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer. Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A Tumori; 2014; 100(2):122-7. PubMed ID: 24852854 [TBL] [Abstract][Full Text] [Related]
3. Multitarget stool DNA testing for colorectal-cancer screening. Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800 [TBL] [Abstract][Full Text] [Related]
4. Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study. Klepp P; Kisiel JB; Småstuen MC; Røseth A; Andersen SN; Vatn MH; Ahlquist DA; Moum BA; Brackmann S Scand J Gastroenterol; 2018 Mar; 53(3):273-278. PubMed ID: 29313389 [TBL] [Abstract][Full Text] [Related]
5. Options for screening for colorectal cancer. Atkin W Scand J Gastroenterol Suppl; 2003; (237):13-6. PubMed ID: 12797674 [TBL] [Abstract][Full Text] [Related]
6. Fecal Genetic Mutations and Human DNA in Colorectal Cancer and Polyps Patients. Lima J; Teixeira Y; Pimenta C; Felipe AV; Silva TD; Junior EEDL; Saad SS; Deak E; Murray H; Manoukian Forones N Asian Pac J Cancer Prev; 2019 Oct; 20(10):2929-2934. PubMed ID: 31653137 [TBL] [Abstract][Full Text] [Related]
7. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Zou H; Taylor WR; Harrington JJ; Hussain FT; Cao X; Loprinzi CL; Levine TR; Rex DK; Ahnen D; Knigge KL; Lance P; Jiang X; Smith DI; Ahlquist DA Gastroenterology; 2009 Feb; 136(2):459-70. PubMed ID: 19026650 [TBL] [Abstract][Full Text] [Related]
8. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011). Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192 [TBL] [Abstract][Full Text] [Related]
9. Controversies in colorectal cancer screening. Pox CP Digestion; 2014; 89(4):274-81. PubMed ID: 25034478 [TBL] [Abstract][Full Text] [Related]
10. Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening. Koga Y; Yamazaki N; Takizawa S; Kawauchi J; Nomura O; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y Anticancer Res; 2014 Jan; 34(1):169-76. PubMed ID: 24403458 [TBL] [Abstract][Full Text] [Related]
11. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612 [TBL] [Abstract][Full Text] [Related]
12. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Schroy PC; Heeren TC Am J Prev Med; 2005 Feb; 28(2):208-14. PubMed ID: 15710277 [TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of screening strategies for colorectal cancer. Barzi A; Lenz HJ; Quinn DI; Sadeghi S Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881 [TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test. Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078 [TBL] [Abstract][Full Text] [Related]
15. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?]. Quintero E Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340 [TBL] [Abstract][Full Text] [Related]
16. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study. Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608 [TBL] [Abstract][Full Text] [Related]
17. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening. Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667 [TBL] [Abstract][Full Text] [Related]
18. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT. Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016 [TBL] [Abstract][Full Text] [Related]
19. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms. Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327 [TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase. Caviglia GP; Cabianca L; Fagoonee S; Gili FM Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]